^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BPI-460372

    i
    Other names: BPI-460372
    Associations

    News

    Trials
    Company:
    Betta Pharma
    Drug class:
    TEAD inhibitor
    Related drugs:
    Associations

    News

    Trials
    10ms
    In vitro and In vivo Drug Metabolism Analysis of BPI-460372 - A Covalent TEAD1/3/4 Inhibitor. (PubMed, Curr Drug Metab)
    This study elucidated the metabolism of BPI-460372 and provided a basis for pharmacokinetic and toxicological species selection, human pharmacokinetics prediction, and assessment of clinical co-administration limitations and possible metabolic pathways in humans.
    Preclinical • Journal
    |
    CYP1A2 (Cytochrome P450, family 1, subfamily A, polypeptide 2) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4) • TEAD1 (TEA Domain Transcription Factor 1)
    |
    BPI-460372
    almost2years
    A Study of BPI-460372 in Advanced Solid Tumor Patients (clinicaltrials.gov)
    P1, N=82, Recruiting, Betta Pharmaceuticals Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    LATS1 (Large Tumor Suppressor Kinase 1)
    |
    LATS1 mutation
    |
    BPI-460372
    over2years
    Phase 1 Study of BPI-460372 in Advanced Solid Tumor Patients (clinicaltrials.gov)
    P1, N=82, Not yet recruiting, Betta Pharmaceuticals Co., Ltd.
    New P1 trial • Metastases
    |
    LATS1 (Large Tumor Suppressor Kinase 1)
    |
    LATS1 mutation
    |
    BPI-460372